在老年男性中,可能的慢性疼痛,大脑结构和阿尔茨海默病的血生物标志物
Tyler R Bell1, Carol E Franz1, Lisa T Eyler2
1Department of Psychiatry, University of California San Diego, San Diego, La Jolla, California; Center for Behavior Genetics of Aging, University of California, San Diego, La Jolla, California.
The journal of pain
|January 10, 2024
概括
男性的慢性疼痛与大脑变化和阿尔茨海默病生物标志物有关. 这表明中年疼痛管理可能会降低痴呆症风险.
科学领域:
- 神经科学是一个神经科学.
- 老年学是指老年学的学科.
- 医学研究 医学研究
背景情况:
- 众所周知,慢性疼痛会导致老鼠的积和海马缩.
- 评估慢性疼痛对人类大脑结构和阿尔茨海默病 (AD) 生物标志物的影响至关重要.
研究的目的:
- 为了研究可能的慢性疼痛与人类海马体积之间的联系.
- 为了检查结点 (LC) 的完整性,这是沉积的关键地点.
- 评估与阿尔茨海默病相关的血生物标志物,在患有和没有慢性疼痛的个体中.
主要方法:
- 68岁时利用结构磁共振成像 (MRI) 测量海马体体积和LC完整性 (LC对比与噪声比).
- 根据在多个研究波 (年龄为56,62,68) 中报告的中度至重度疼痛,定义了可能的慢性疼痛.
- 分析了血生物标志物 (总tau,β-胺-42,β-胺-40) 并根据健康状况,抑郁症和阿片类药物使用等混因素进行调整.
主要成果:
- 可能患有慢性疼痛的男性呈现较小的海马体积.
- 在可能患有慢性疼痛的男性中观察到下面的正面-中间LC完整性 (对比与噪声比).
- 在可能患有慢性疼痛的男性中发现了总tau,β-粉胺-42和β-粉胺-40的血水平升高.
结论:
- 可能的慢性疼痛与大脑结构完整性降低和陶积累增加有关,反映了阿尔茨海默病的早期变化.
- 研究结果表明,慢性疼痛与与阿尔茨海默氏症发展有关的生物学途径之间存在联系.
- 针对中年期疼痛的干预措施可能会减轻晚年阿尔茨海默病的风险.
更多相关视频
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
865
06:22A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid
Published on: September 3, 2021
3.7K
相关概念视频
Alzheimer's Disease: Overview
490
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
490
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Dementia
115
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
115
